Medicure Inc.MPH.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · medicure.com
Medicure Inc. is a Canadian pharmaceutical company focused on the development and commercialization of cardiovascular therapeutics, primarily in the U.S. market. The company markets AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets through its U.S. subsidiary, Medicure Pharma Inc. It also operates Marley Drug, an online pharmacy serving patients across all 50 U.S. states.
Key ratios
FCF / Sales
6.6%TTM
2024
6.3%2023
9.6%2022
7.9%
Net margin
-13.1%TTM
2024
-4.7%2023
-4.3%2022
5.9%
ROA
-6.5%TTM
2024
-5.9%2023
-1.8%2022
2.6%
ROE
-18.4%TTM
2024
-5.1%2023
-4.5%2022
6.9%
Recent news
Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
MEDICURE ANNOUNCES AGM RESULTS AND APPOINTMENT OF NEW DIRECTOR
Track MPH.V in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer